Titan Pharmaceuticals Announces Rigorous Sensitivity Analyses Confirm Effectiveness of Probuphine(R) for Opioid Dependence June 15, 2016
Titan Pharmaceuticals Receives $15 Million Milestone Payment Following FDA Approval of Probuphine(R) June 13, 2016
Titan Pharmaceuticals Announces FDA Approval of Probuphine(R) for the Treatment of Opioid Dependence May 26, 2016
Titan Pharmaceuticals Schedules Conference Call to Review First Quarter 2016 Financial Results May 4, 2016
Titan Pharmaceuticals Announces Presentation of Probuphine Phase 3 Data at American Society of Addiction Medicine Annual Conference April 15, 2016
Titan Pharmaceuticals Schedules Conference Call to Review Fourth Quarter and Full Year 2015 Financial Results March 8, 2016
Titan Pharmaceuticals Receives Feedback From FDA on Ropinirole Implant Development Program for Parkinson's Disease March 7, 2016
